Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,615,851
  • Shares Outstanding, K 62,041
  • Annual Sales, $ 63,630 K
  • Annual Income, $ -766,800 K
  • 60-Month Beta 1.01
  • Price/Sales 73.94
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BHVN with:

Options Overview

Details
  • Implied Volatility 58.04%
  • Historical Volatility 51.01%
  • IV Percentile 3%
  • IV Rank 4.32%
  • IV High 125.63% on 01/05/21
  • IV Low 54.99% on 03/26/21
  • Put/Call Vol Ratio 0.39
  • Today's Volume 443
  • Volume Avg (30-Day) 556
  • Put/Call OI Ratio 1.20
  • Today's Open Interest 11,865
  • Open Int (30-Day) 10,464

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -2.99
  • Number of Estimates 4
  • High Estimate -2.59
  • Low Estimate -3.56
  • Prior Year -2.39
  • Growth Rate Est. (year over year) -25.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.57 +16.89%
on 03/30/21
76.91 -4.91%
on 04/14/21
+2.67 (+3.78%)
since 03/19/21
3-Month
62.57 +16.89%
on 03/30/21
93.54 -21.81%
on 01/27/21
-4.69 (-6.03%)
since 01/19/21
52-Week
37.92 +92.87%
on 04/20/20
100.77 -27.42%
on 11/18/20
+34.73 (+90.41%)
since 04/17/20

Most Recent Stories

More News
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 22 abstracts, including three oral presentations, were accepted at the 2021 American Academy of Neurology...

BHVN : 72.21 (-2.94%)
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Jumps 8.5%: Will It Continue to Soar?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest...

BHVN : 72.21 (-2.94%)
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT

, /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today...

BHVN : 72.21 (-2.94%)
Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members

, /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day...

BHVN : 72.21 (-2.94%)
Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: ), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative,...

BHVN : 72.21 (-2.94%)
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of...

BHVN : 72.21 (-2.94%)
Biohaven Announces Proposed Public Offering Of Common Shares

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative,...

BHVN : 72.21 (-2.94%)
Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced today that more than 50% of participants have been enrolled in the verdiperstat regimen...

BHVN : 72.21 (-2.94%)
Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

BIIB : 267.94 (-0.88%)
CPRX : 4.32 (-2.70%)
BHVN : 72.21 (-2.94%)
SAVA : 34.10 (-2.15%)
Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine

, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Medison Pharma announced today that NURTEC® ODT (rimegepant) was approved by the Israeli Ministry of Health for...

BHVN : 72.21 (-2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which...

See More

Key Turning Points

3rd Resistance Point 79.05
2nd Resistance Point 77.95
1st Resistance Point 76.17
Last Price 72.21
1st Support Level 73.29
2nd Support Level 72.19
3rd Support Level 70.41

See More

52-Week High 100.77
Fibonacci 61.8% 76.76
Last Price 72.21
Fibonacci 50% 69.35
Fibonacci 38.2% 61.93
52-Week Low 37.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar